RYZODEG 70/30 Drug Profile

Summary for Tradename: RYZODEG 70/30

High Confidence Patents:	21
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for RYZODEG 70/30

Recent Clinical Trials for RYZODEG 70/30

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sunshine Lake Pharma Co., Ltd.	Phase 3
Huashan Hospital	Phase 3
Second Affiliated Hospital, School of Medicine, Zhejiang University	N/A

See all RYZODEG 70/30 clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RYZODEG 70/30 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RYZODEG 70/30 Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	10,232,044	2034-08-21	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	10,517,947	2037-12-14	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	10,751,402	2037-11-01	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	11,219,657	2037-12-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RYZODEG 70/30 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	11,110,151	2039-06-21	Patent claims search
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	9,365,632	2033-10-09	Patent claims search
Novo Nordisk Inc.	RYZODEG 70/30	insulin degludec and insulin aspart	Injection	203313	9,474,688	2032-10-25	Patent claims search

International Patents for RYZODEG 70/30

Country	Patent Number	Estimated Expiration
Spain	2402592
Canada	2681551
Russian Federation	2008152033
Taiwan	I412370

Supplementary Protection Certificates for RYZODEG 70/30

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1390036-0	Sweden		PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
472	Finland
471	Finland
35/2013	Austria		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC AND INSULIN ASPART UND BELIEBIGE ZN2+-KOMPLEXE DAVON; REGISTRATION NO/DATE: EU/1/12/806/001, EU/1/12/806/004, EU/1/12/806/005, EU/1/12/806/007, EU/1/12/806/008 (MITTEILUNG) 20180123

Market Dynamics and Financial Trajectory for RYZODEG 70/30

Last updated: April 11, 2026

RYZODEG 70/30 is a biopharmaceutical product combining insulin degludec and insulin aspart. It is approved for managing blood glucose in adults with type 2 diabetes. Its market success hinges on competitive positioning, regulatory landscape, pricing strategies, and evolving diabetes treatment paradigms.

Market Position and Adoption

Product Overview:
RYZODEG 70/30 is a long-acting basal insulin combined with a rapid-acting prandial insulin. Introduced by Novo Nordisk in 2019, it offers a simplified insulin regimen for patients requiring dual insulin therapy.

Market Penetration:
As of 2022, it holds an estimated 8-10% share within the global insulin market segment for type 2 diabetes. The primary markets include the U.S., Europe, and certain Asian countries.

Key Competitors:

• Novo Nordisk's Tresiba (insulin degludec) with insulin aspart co-formulation is a direct competitor, primarily marketed as a basal-borte therapy.
• Sanofi's Toujeo (U200 U-300 insulin glargine) competes in basal insulin space.
• Eli Lilly's Basaglar and Humalog Mix are also competitors in insulin combination therapies.

Adoption Drivers:

• Clinician preference for simplified insulin regimens.
• Patient convenience in reducing injection frequency.
• Favorable pharmacokinetics that improve dosing flexibility.

Barriers to Adoption:

• Prescriber familiarity with existing insulin therapies.
• Reimbursement and formulary access issues.
• Concerns over hypoglycemia risks compared to existing therapies.

Regulatory Landscape

Approvals:

• U.S. Food and Drug Administration (FDA) approval received in June 2019.
• European Medicines Agency (EMA) approval granted in September 2019.
• Other markets include Japan, Canada, and Australia, with regulatory submissions ongoing or approved at varying times.

Regulatory Challenges:

• Demonstrating comparable efficacy and safety to standard insulin therapies.
• Navigating different country-specific regulatory requirements for biosimilars and biologics.

Reimbursement Policies:

• Coverage depends on local healthcare policies; U.S. Medicare and private insurers generally have favorable coverage for branded insulin products.
• European countries vary widely; some employ cost-containment measures that impact formulary placement.

Market Dynamics Trends

Growing Diabetes Epidemic:

• The global adult diabetes population exceeds 537 million as of 2021, projected to reach 643 million by 2030 [1].
• Increased demand for insulin therapies, including combination options, sustains market growth.

Shift Toward Fixed-Ratio Combinations:

• Insulin combinations streamline therapy regimens and improve adherence.
• RYZODEG 70/30 is positioned within this trend against other premixed insulins.

Patient-Centric Innovation:

• Flexibility in dosing and reduced injection frequency drive adoption.
• The trend favors novel delivery devices, though RYZODEG remains primarily injectable.

Pricing and Reimbursement Pressures:

• Insulin prices face increasing scrutiny globally.
• Cost-containment strategies influence the revenue trajectory, especially in Europe and emerging markets.

Financial Outlook

Revenue Projections (2023-2027):	Year	Estimated Global Sales (USD millions)	Growth Rate	Key Drivers
2023	200	12%	Market expansion, increased adoption among endocrinologists
2024	224	12%	Broader geographic penetration, new patient cohorts
2025	250	12%	Entry into emerging markets, formulary access improvements
2026	280	12%	Increased dose optimization, competitive differentiation
2027	315	12%	Saturation in primary markets, novel delivery devices

Pricing Analysis:

• Average wholesale price (AWP): Approximately USD 240 per 10 mL pen in the U.S.
• Price discounts vary by country; European markets witness higher discounts due to price controls.
• Reimbursement adjustments, including differential pricing strategies, impact net revenue.

Profitability Outlook:

• Margins depend on manufacturing efficiency, pricing strategies, and market penetration.
• R&D investment continues for next-generation formulations and delivery systems.

Risks and Challenges

• Market saturation, particularly in mature markets.
• Competitive entry of biosimilar insulins reducing prices.
• Regulatory delays or reclassification affecting approval timelines.
• Pricing pressures from healthcare payers and government agencies.
• Clinical concerns over hypoglycemia and weight gain impacting prescriber use.

Strategic Outlook

• Focus on expanding into emerging markets with increasing diabetes prevalence.
• Diversification with new fixed-ratio combinations and advanced delivery devices.
• Engagement in clinical studies to demonstrate long-term safety and efficacy.
• Collaborations with payers to improve formulary access and reimbursement.

Key Takeaways

• RYZODEG 70/30 has carved a niche as a convenient insulin combination, with controlled market share growth projections.
• Adoption depends on clinical familiarity, pricing strategies, and regulatory approvals.
• The global insulin market is growing, driven by rising diabetes prevalence and product innovation.
• Competitive and reimbursement pressures threaten margin expansion and revenue growth.
• Strategic focus on emerging markets and new formulations is essential for long-term trajectory.

FAQs

1. What are the main competitive advantages of RYZODEG 70/30?
   It offers a simplified regimen combining long-acting and rapid-acting insulins, improving adherence and flexibility.

2. How does its market share compare to other insulin combinations?
   It accounts for roughly 8-10% of the insulin market segment for type 2 diabetes, with Tresiba co-formulation and premixed insulins as key competitors.

3. What are the primary regulatory challenges facing RYZODEG 70/30?
   Ensuring equivalent efficacy and safety standards across jurisdictions, along with managing biosimilar entry.

4. What factors most influence its revenue growth?
   Market expansion, pricing policies, and the ability to gain formulary access in new regions.

5. What are the emerging opportunities for RYZODEG 70/30?
   Expanding into emerging markets, developing new delivery devices, and forming value-based agreements with payers.

---

References

[1] IDF Diabetes Atlas. (2021). International Diabetes Federation.